US 12,251,444 B2
Compositions and methods for delivering an agent to a wound
Warren O. Haggard, Memphis, TN (US); Scott P. Noel, Memphis, TN (US); and Joel D. Bumgardner, Memphis, TN (US)
Assigned to UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION, Memphis, TN (US)
Filed by The University of Memphis Research Foundation, Memphis, TN (US)
Filed on Jan. 27, 2023, as Appl. No. 18/102,123.
Application 18/102,123 is a continuation of application No. 17/027,318, filed on Sep. 21, 2020, granted, now 11,576,975.
Application 17/027,318 is a continuation of application No. 16/050,508, filed on Jul. 31, 2018, granted, now 10,799,592, issued on Oct. 13, 2020.
Application 16/050,508 is a continuation of application No. 15/483,686, filed on Apr. 10, 2017, granted, now 10,052,388, issued on Aug. 21, 2018.
Application 15/483,686 is a continuation of application No. 14/618,722, filed on Feb. 10, 2015, granted, now 9,642,948, issued on May 9, 2017.
Application 14/618,722 is a continuation of application No. 13/256,585, granted, now 8,993,540, issued on Mar. 31, 2015, previously published as PCT/US2010/027481, filed on Mar. 16, 2010.
Claims priority of provisional application 61/227,606, filed on Jul. 22, 2009.
Claims priority of provisional application 61/171,805, filed on Apr. 22, 2009.
Claims priority of provisional application 61/160,539, filed on Mar. 16, 2009.
Prior Publication US 2023/0226190 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C08B 31/04 (2006.01); A61K 9/70 (2006.01); A61K 31/00 (2006.01); A61K 31/7036 (2006.01); A61K 38/14 (2006.01); A61K 47/36 (2006.01); A61L 15/28 (2006.01); A61L 15/44 (2006.01); A61L 27/20 (2006.01); A61L 27/58 (2006.01); A61L 29/04 (2006.01); A61L 29/14 (2006.01); A61L 29/16 (2006.01); A61L 31/04 (2006.01); A61L 31/14 (2006.01); A61L 31/16 (2006.01); C08B 37/08 (2006.01); C08J 5/18 (2006.01); C08L 5/08 (2006.01); A61K 9/00 (2006.01)
CPC A61K 47/36 (2013.01) [A61K 9/7007 (2013.01); A61K 31/00 (2013.01); A61K 31/7036 (2013.01); A61K 38/14 (2013.01); A61L 15/28 (2013.01); A61L 15/44 (2013.01); A61L 27/20 (2013.01); A61L 27/58 (2013.01); A61L 29/043 (2013.01); A61L 29/146 (2013.01); A61L 29/148 (2013.01); A61L 29/16 (2013.01); A61L 31/042 (2013.01); A61L 31/146 (2013.01); A61L 31/148 (2013.01); A61L 31/16 (2013.01); C08B 37/003 (2013.01); C08J 5/18 (2013.01); C08L 5/08 (2013.01); A61K 9/0024 (2013.01); A61L 2300/232 (2013.01); A61L 2300/25 (2013.01); A61L 2300/406 (2013.01); C08J 2305/08 (2013.01)] 4 Claims
 
1. A medical device for implantation comprising an acid-treated chitosan composition, prepared by a method comprising:
(a) dissolving chitosan in one or more acids in an aqueous solvent;
(b) forming the chitosan of step (a) into a film by pouring the chitosan into a thin layer and heating the chitosan to form a dehydrated chitosan film;
(c) lyophilizing the chitosan film under conditions that reduce the water content by about 10%-100%;
(d) neutralizing the chitosan film by contacting the film with water, a neutral, or a basic solution, wherein the water, neutral, or basic solution is selected to modulate a physical-mechanical property of the fiber;
(e) washing the chitosan film with water until neutral; and
(f) lyophilizing the film of step (e) to reduce the water content by about 80%-100%, thereby producing a biodegradable chitosan film.